ReVision Optics (RVO) a research and development company specializing in implantable microlens technology, has appointed John Kilcoyne as chief executive officer and president.
Kilcoyne will succeed Randy Alexander, who will assume the role of chairman of the Board.
Kilcoyne, having experienced in the medical device market, served as chairman and CEO of Micrus Endovascular until its sale to Johnson & Johnson
RVO chairman Alexander said John’s broad range of experience in the medical device industry and his demonstrated ability to understand the needs of patients and physicians made him the best person for this position.
"As RVO moves from our research and development stage into commercialization it’s more important than ever to have someone with John’s background at the helm. We are delighted that he has joined our company," Alexander said.
Kilcoyne also previously served as president and chief executive officer of Solace Therapeutics from 2002 to 2004 and Endonetics from 1997 until its acquisition by Medtronic in December 2001.